Highlights from the DIA Ad-Promo Regulatory Affairs Conference 2017 An interactive session facilitated by: Glenn N. Byrd, MBA, RAC Senior Director, Specialty Care Promotional Regulatory Affairs AstraZeneca, United States (DIA Ad-Promo Program Committee Member)

DIA Ad-Promo Regulatory Affairs Conference 2017 Meeting Summary Day 1 Morning - All about FDA Afternoon – 2 breakouts and 1 Off-label comm talk Close with FDA Q&A Day 2 Early Morning Working Group Overview Re-cap of Day 1 2 sets of breakouts Patient Support Programs FDA in the Trump administration

FDA Enforcement Overview FDA Draft Guidance and Initiatives Day 1 FDA Enforcement Overview FDA Draft Guidance and Initiatives OPDP Research Agenda Breakouts Proactive communications to Population Health Decision Makers Live and Field based tactics Navigating the Murky Waters of Off-Label Communications Q&A with FDA

Early morning session – DIA Ad-Promo Working Group Re-cap of Day 1 Mobile Apps – Promotion or Device? Breakouts Ad-Promo’s role in adoption of technology in our companies Digital tactics Developing a productive ad-promo team Building and maintaining a productive FDA ad-promo relationship Patient Support Programs FDA in the Trump Administration